Literature DB >> 909314

Vancomycin.

J E Geraci.   

Abstract

Vancomycin, a useful bactericidal antibiotic for selective clinical infections, is the therapy of choice for serious staphylococcal infections when the penicillins and cephalosporins cannot be used. The antibacterial spectrum of vancomycin also covers other gram-positive cocci and bacteria and gram-negative cocci. Vancomycin is given intravenously in most cases, usually in a dose of 1 g every 12 hours in patients who have normal renal function. The indications for vancomycin therapy are as follows. 1. Serious staphylococcal infections in patients who are intolerant to the penicillins and cephalosporins or when the organism is resistant to the commonly used bactericidal agents. 2. Streptococcal endocarditis in patients intolerant to penicillin G; in enterococcal infections, it is used with an associated aminoglycoside. Vancomycin is not used alone in enterococcal endocarditis. In nonenterococcal (Streptococcus bovis) and viridans streptococcal endocarditis, vancomycin may be used alone if the minimum bactericidal concentration is less than or equal to 10 microgram/ml; otherwise, it is combined with an aminoglycoside. 3. Other serious infections caused by organisms resistant to the commonly used agents such as corynebacterial endocarditis. 4. Acute staphylococcal ileocolitis, for which vancomycin is given orally or orally and intravenously if indicated. Vancomycin is relatively nontoxic; the predominant toxic response is neurotoxicity, but this is rarely seen if the serum levels are 30 microgram/ml or less.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 909314

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  19 in total

Review 1.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Comparison of Continuous and Intermittent IV Infusion of Vancomycin: Systematic Review.

Authors:  Sally S K Man; Roxane R Carr; Mary H H Ensom
Journal:  Can J Hosp Pharm       Date:  2010-09

4.  Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults.

Authors:  N Maki; A Ohkuchi; Y Tashiro; M R Kim; M Le; T Sakamoto; S Matsubara; Y Hakamata
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-06       Impact factor: 3.267

5.  Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model.

Authors:  S B Duffull; E J Begg; S T Chambers; M L Barclay
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

6.  Evaluation of an automated fluorescence polarization immunoassay for vancomycin.

Authors:  B H Filburn; V H Shull; Y M Tempera; J D Dick
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

7.  Comparison of fluorescence polarization immunoassay and bioassay of vancomycin.

Authors:  D J Pohlod; L D Saravolatz; M M Somerville
Journal:  J Clin Microbiol       Date:  1984-08       Impact factor: 5.948

8.  Gentamicin-resistant enterococci and endocarditis.

Authors:  R Holliman; E Smyth
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

9.  Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits.

Authors:  P Tattevin; A Saleh-Mghir; B Davido; I Ghout; L Massias; C Garcia de la Maria; J M Miró; C Perronne; F Laurent; A C Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

10.  Vancomycin pharmacokinetics in normal and morbidly obese subjects.

Authors:  R A Blouin; L A Bauer; D D Miller; K E Record; W O Griffen
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.